Akero Therapeutics, part of a cohort of biotechs attempting to mark a turnaround in NASH drug development, did not pass the bar in a Phase IIb test of patients with cirrhosis, the most severe form of the fatty liver disease that is also known as stage F4.
The South San…
Click here to view original post
